Tenax Therapeutics, Inc.

TENX Nasdaq SEC CIK 34956
Follow Tenax Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$16.7M −5.7% vs same quarter last year
EPS, diluted −$0.31 +22.5% vs same quarter last year
Operating cash flow −$12.5M −36.3% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$52.6M
FY24$0−$17.6M
FY23-−$7.7M
FY22-$11M
FY21-−$32.5M
FY20-−$9.9M
FY19-−$8.4M
FY18-−$14.1M
FY17-−$8.8M
FY16$0−$43.9M
FY15$49.3K−$14.1M
FY14$158.9K−$19.5M
FY13$1.2M−$9.4M
FY12$363.8K−$15.7M
FY11$103.2K-
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−40000%−20000%0%20000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY22---
FY21---
FY20---
FY19---
FY18---
FY17---
FY16---
FY150%−30062.8%−28571.6%
FY14−65.5%−10452.1%−12296.2%
FY134.2%−435.7%−790.6%
FY1213.5%−2259.7%−4319.2%
FY11100%10238.4%-
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$11.4M
FY21−$10.9M
FY20−$9.3M
FY19−$7.6M
FY18−$5.5M
FY17−$12.1M
FY16−$15.9M
FY15−$9.8M
FY14−$9.3M
FY13−$4.9M
FY12−$8.3M
FY11−$8.6M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Tenax Therapeutics
  • Healthcare median
−30000%−20000%−10000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearTenax TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15−28571.6%−37.8%
FY14−12296.2%−35.5%
FY13−790.6%−37.1%
FY12−4319.2%−29.1%
FY11-−27.9%